TITLE

A Review of Recent Clinical Experience with Almotriptan

AUTHOR(S)
Diener, Hans-Christoph
PUB. DATE
September 2006
SOURCE
Drugs;2006 Supplement, Vol. 66, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The purpose of this paper is to review six recently completed trials (three double-blind, three open-label) providing valuable data on efficacy and tolerability of almotriptan in 'real world' settings. In a randomized double-blind trial, almotriptan 12.5 mg and zolmitriptan 2.5 mg achieved similar efficacy rates whereas almotriptan was associated with a lower rate of triptan-associated adverse events (AE). In another randomized double-blind trial, almotriptan patients achieved significantly higher 2-h pain-free, 2-h pain-relief and sustained pain-free rates than those receiving ergotamine plus caffeine. A third double-blind trial, enrolling patients with a history of poor response to sumatriptan (confirmed in a prerandomization attack), showed that patients receiving almotriptan had significantly higher 2-h pain-free, 2-h pain-relief and sustained pain-free rates compared with those receiving placebo. An open-label trial found similar rates of preference for almotriptan and rizatriptan 10 mg; similar rates were also seen for 2-h pain free, 2-h pain relief and sustained pain free. The German Migraine Register (open-label) found triptans to be associated with greater treatment satisfaction than non-specific agents; almotriptan and sumatriptan were linked to the highest levels of patient satisfaction. Another open-label satisfaction study showed that in comparison with previous therapies, almotriptan was associated with higher rates of pain relief, tolerability, resumption of normal activities, and the use of only one dose. In summary, the high levels of efficacy and tolerability reported for almotriptan 12.5 mg in earlier placebo-controlled clinical trials can be reproduced in 'real-world' clinical settings, and are consistent with previous trials showing almotriptan to have the ideal profile for an acute migraine treatment, that is, a balance between high efficacy and low AEs.
ACCESSION #
23606095

 

Related Articles

  • Evaluation of Efficacy, Tolerability, and Treatment Satisfaction with Almotriptan in 3 Consecutive Migraine Attacks. Massiou, Hélène; Pradalier, Andre; Donnet, Anne; Lanteri-Minet, Michel; Allaf, Bashar // European Neurology;2006, Vol. 55 Issue 4, p198 

    The objective of the open-label, multicenter Migraine – Satisfaction with Treatment: Reality with Almogran® study was to assess efficacy, tolerability, and satisfaction with almotriptan 12.5 mg among migraineurs who were not achieving adequate results with their current acute therapy....

  • N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis. Millán-Guerrero, R.O.; Isais-Millán, R.; Guzmán-Chávez, B.; Castillo-Varela, G. // Canadian Journal of Neurological Sciences;Mar2014, Vol. 41 Issue 2, p233 

    The article presents the study on the effectiveness and tolerability of N alpha methyl histamine compared with propanolol in the treatment of migraine prophylaxis. It discusses how the study was conducted which involved 60 migraine patients who underwent a 12-week double-blind controlled...

  • Pain. Matus, Jordan; Harrar, Sarí // Prevention;Feb2002, Vol. 54 Issue 2, p156 

    Presents information about pain relief, including how so-called sinus headaches may respond better to migraine medications.

  • Headache from the Doctors' Perspective. Gil-Gouveia, Raquel // European Neurology;Apr2014, Vol. 71 Issue 3/4, p157 

    Background: General practitioners (GPs) and neurologists are involved in treating headache patients in Portugal. Having migraine themselves might influence the way they perceive and treat migraine patients. Objective: To identify clinicians' perceptions about migraine, their own headache status...

  • Review: Several drugs, especially triptans, are effective for pain relief in acute migraine. Loder, Elizabeth // ACP Journal Club;Nov/Dec2002, Vol. 137 Issue 3, p103 

    Discusses research being done on pharmacologic treatments for pain relief in patients with migraine. Reference to study by A.D. Oldman and colleagues, published in the June 2002 issue of the journal 'Pain'; Sources of data; Effectiveness of pharmacological treatments.

  • Lavender Essential Oil in the Treatment of Migraine Headache: A Placebo-Controlled Clinical Trial. Sasannejad, Payam; Saeedi, Morteza; Shoeibi, Ali; Gorji, Ali; Abbasi, Maryam; Foroughipour, Mohsen // European Neurology;2012, Vol. 67 Issue 5, p288 

    Lavender essential oil has been used as an anxiolytic drug, a mood stabilizer, a sedative, spasmolytic, antihypertensive, antimicrobial, analgesic agent as well as a wound healing accelerator. We have studied for the first time the efficacy of lavender essential oil inhalation for the treatment...

  • Pain management in the pharmacy: headaches. Whittaker, C. // South African Pharmacist's Assistant;Autumn2011, Vol. 11 Issue 1, p14 

    The article focuses on the management of headache. It notes that headache is a common medical ailment among patients who ask for medications in the pharmacy, urging pharmacist's assistants to educate patients on how to safely use over-the-counter (OTC) drugs. It mentions that 90 percent of...

  • Headache. Kernick, David // Update;Jan2007, Vol. 74 Issue 1, p16 

    The article provides an overview on headache as well as the key areas of progress in headache care. It states that headache is classified as primary, if there is no identifiable cause, or secondary, when an underlying cause is known. Key information is presented which outlines the categories of...

  • Allodynia and migraine. Aguggia, Marco // Neurological Sciences;Feb2012, Vol. 33, p9 

    An impaired processing of sensory afferents in the brainstem plays a key role in the development of migraine attack and for many of its clinical aspects. The repetition or prolonged of painful stimuli over time would be able to produce a prolonged and reversible increase of excitability and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics